The stock is now trading near the $17.00 acquisition price, so the primary remaining catalyst is the closing of the Zymeworks deal, expected in H2 2026. Monitor for shareholder vote date and any regulatory conditions. The CVR component provides a speculative tail on ampreloxetine development by Zymeworks.
Price Chart
Executive Summary
Theravance Biopharma reported Q2 2026 earnings with no analyst consensus provided for the current period. The filing is dominated by the pending acquisition by Zymeworks for $17.00 per share in cash plus a CVR, expected to close in H2 2026. YUPELRI collaboration revenue grew 11% YoY to $20.7M, and the company posted a GAAP net loss of $5.9M vs net income of $54.8M in Q2 2025 (which included a $75.1M one-time gain). Non-GAAP net income from operations was $9.5M vs a loss of $4.2M a year ago.
Key Financial Metrics
Key Facts
- Pending acquisition by Zymeworks at $17.00 per share in cash plus a CVR entitling shareholders to 80% of future ampreloxetine monetization proceeds over 10 years.
- YUPELRI collaboration revenue increased 11% year-over-year to $20.7 million in Q2 2026.
- GAAP net loss of $5.9 million in Q2 2026 vs net income of $54.8 million in Q2 2025 (which included a $75.1M net gain on realized royalty assets).
- Non-GAAP net income from operations was $9.5 million in Q2 2026 vs a non-GAAP net loss of $4.2 million in Q2 2025.
- Cash, cash equivalents and marketable securities totaled $387.7 million with no debt as of June 30, 2026.
- Operating expenses (excluding restructuring and transaction costs) decreased 35% year-over-year.
- Restructuring on track to deliver ~$60-70 million of annualized cash flow starting H2 2026.
Financial Impact
Zymeworks acquisition at $17.00 per share cash represents a fixed premium over the pre-announcement trading price, plus a CVR for potential additional value from ampreloxetine. YUPELRI revenue grew 11% YoY to $20.7M. Cash position is $387.7M with no debt.
Risk Factors
- Transaction may not close or may be delayed if shareholder approval or regulatory conditions are not met.
- CVR value is uncertain and depends entirely on Zymeworks' ability to monetize ampreloxetine within 10 years.
- GAAP net loss continued in Q2 2026 ($5.9M), though restructuring is expected to deliver positive annualized cash flow by H2 2026.
- TRELEGY milestone payment of $100 million depends on GSK achieving ~$3.5B in 2026 global net sales — not guaranteed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-093066 |
| Document: tm2622638d1_8k.htm | 0001104659-26-093066 |
| Document: 0001104659-26-093066-index-headers.html | 0001104659-26-093066 |
| Document: 0001104659-26-093066-index.html | 0001104659-26-093066 |
| Document: 0001104659-26-093066.txt | 0001104659-26-093066 |
| 8-K Data (Synthetic) | 0001104659-26-093066 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | DEFA14A | $17.03 $17.03 | · 0.00% | ▼ −0.23% | — |
Aug 21, 2026 6w ago | DEFM14A | $17.01 $17.05 | ▲ +0.24% | ▲ +0.76% | — |
Aug 11, 2026 7w ago | PREM14A | $16.91 $17.06 | ▲ +0.89% | ▲ +1.95% | — |
Aug 10, 2026 7w ago | 8-K | $16.91 $17.06 | ▲ +0.89% | ▲ +1.80% | — |
Jun 29, 2026 13w ago | 8-K | $17.06 $16.86 | ▼ −1.17% | ▼ −0.89% | — |
Jun 23, 2026 14w ago | 8-K | $17.27 $16.81 | ▼ −2.66% | ▼ −4.60% | — |
May 7, 2026 21w ago | 8-K | $17.02 $15.92 | ▼ −6.46% | ▼ −9.60% | — |
Mar 3, 2026 30w ago | 8-K | $13.96 $16.23 | ▼ −16.26% | ▼ −20.66% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access